The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Global ...

Apotex Inc., Canada’s largest drug maker, has won Health Canada approval to sell a generic form of the blockbuster Ozempic. The Toronto-based company is the second manufacturer to get an approval, ...

April 28 (Reuters) - Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes drug Ozempic made by Indian drugmaker Dr ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...

LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

Learn about the best practices for concurrency in Java to ensure your multi-threaded applications are efficient, synchronized, and error-free. Concurrency in Java is the ability of multiple threads to ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...